Wolfe Research analyst Andrew Rosivach initiates coverage on Cousins Props (NYSE:CUZ) with a Peer Perform rating.
Harmony Biosciences Completes Enrollment Of Phase 3 Registrational Intune Study In Idiopathic Hypersomnia
Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today